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Abstract
Herein, we assessed whether hepatobiliary phase (HBP) signal intensity (SI) can be used to
differentiate HCC and non-HCC malignancies within LR-M observations. 106 LR-M patients
based on LI-RADS v2018 who underwent gadoxetate-disodium magnetic resonance imag-
ing and surgery from January 2009 to December 2018 were included. SI of LR-M observa-
tion on HBP was analyzed by two radiologists and categorized into dark, low and iso-to-high
groups. Tumor was classified as dark when more than 50% of tumor showed hypointensity
compared to spleen, as low when more than 50% of tumor showed hyperintensity compared
to spleen but hypointensity compared to liver parenchyma, and as iso-to-high if there was
even a focal iso-intensity or hyperintensity compared to liver parenchyma. Analysis of clini-
copathological factors and association between imaging and histology was performed. Out
of 106 LR-M, 42 (40%) were showed dark, 61 (58%) showed low, and 3 (3%) showed iso-to-
high SI in HBP. Three iso-to-high SI LR-M were HCCs (P = 0.060) and their major histologic
differentiation was Edmondson grade 1 (P = 0.001). 43 out of 61 (71%) low SI LR-M were
iCCA or cHCC-CCA (P = 0.002). Inter-reader agreement of HBP SI classification was excel-
lent, with a kappa coefficient of 0.872. LR-M with iso-to-high SI in HBP is prone to being
HCC while LR-M with low SI in HBP is prone to being tumor with fibrous stroma such as
iCCA and cHCC-CCA. Classification of LR-M based on HBP SI may be a helpful method of
differentiating HCC from non-HCC malignancies.
Introduction
The CT/MRI liver imaging reporting and data system (LI-RADS) includes a special category,
LI-RADS M (LR-M) for observations that are probably or definitely malignant but not neces-
sarily hepatocellular carcinoma (HCC) [1]. The aim of this category, when first introduced,
was to maintain the specificity of LR-5 (definitely HCC) without losing the sensitivity to detect
malignancies including HCC with atypical imaging features, intrahepatic mass forming
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cholangiocarcinoma (iCCA) and combined hepatocellular cholangiocarcinoma (cHCC-CCA)
[1, 2]. Although new explicit LR-M criteria have been introduced through LI-RADS v2017
(same in v2018) including targetoid apperance and several nontargetoid imaging features, the
diagnostic performance of LR-M features for non-HCC malignancy has been variable with
reported sensitivity of 9–83% and specificity of 69–97% [3–5]. Not only does the ambiguous
criteria of LR-M makes it susceptible to the subjectivity of each radiologist but also the hetero-
geneous group of disease entities given this category makes it difficult for an accurate imaging
prediction of the likely etiology of LR-M observation [6].
However, differential diagnosis of HCC from non-HCC malignancies on imaging is critical
because pathologic confirmation is not always madated before instituting treatment in case of
HCC and also because HCC differs from non-HCC malignancies such as cHCC-CCA and
iCCA with regards to possible candidacy for liver transplantation and prediction of prognosis
[7, 8]. In such case, it would be important to accurately categorize LR-M HCCs with atypical
imaging features as definitely HCC in patients with Barcelona Clinic Liver Cancer (BCLC)
stage 0/A and Child Pugh class A, who are eligible and can benefit curative treatment from
liver transplantation [9–11]. Likewise, a more accurate image prediction of non-HCC malig-
nancy within LR-M observations by differentiating non-HCC malignancies from HCC with
atypical imaging features may help narrow patients in need and urgency of biopsy. Either way,
a more accurate diagnosis of HCC or non-HCC malignancy among LR-M in patients of high
risk of HCC holds mutual clinical significance for both groups. In addition, most of the previ-
ous studies [12–14] regarding LR-M observations have focused on imaging findings that can
differentiate iCCA or cHCC-CCA from HCC among LR-M observations.
For diagnosing HCC, the use of gadoxetic acid-enhanced MRI is favored over extracellular
agent (ECA)-enhanced MRI in East Asia since maximizing the sensitivity of HCC diagnosis is
justified by the greater use of locoregional therapies such as ablation and transarterial che-
moembolization, and the detection of HCC can be improved by the use of hepatobiliary phase
of gadoxetic acid-enhanced MRI [15–17]. To our knowledge, while there have been studies
analyzing tumor serum markers, imaging findings and deep learning [18, 19], no prior study
has performed a quantitative assessment of the hepatobiliary phase signal intensity in order to
differentiate a LR-M observation. Hence, the purpose of this study was to investigate whether
hepatobiliary phase (HBP) signal intensity can be used to differentiate HCC and non-HCC
malignancies within LR-M observations. In addition, image-histologic correlation was per-




This retrospective study was approved by our institutional review board of Yonsei University
College of Medicine, Severance Hospital (IRB No. 2020-3696-001) and the requirement for
patient consent was waived. Using electronic medical records, patients with underlying liver
cirrhosis or chronic B-viral hepatitis who underwent gadoxetate-disodium enhanced MRI
between January 2009 and December 2018 for the evaluation of a focal hepatic observation
were identified. Patients who (1) underwent surgical resection within 6 months from date of
MRI exam, (2) had not previously been treated for hepatic observation prior to MRI study,
and (3) were pathologically diagnosed via surgery were included. Likewise, patients who (1)
had poor MR image quality and (2) did not have all required images of MRI protocol were
excluded from analysis. Based on these inclusion and exclusion criteria, 1,286 hepatic observa-
tions were eligible for study. The MRI data, surgical notes and pathology reports for the largest
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observation in these patients were retrospectively reviewed. Two radiologists classified these
observations according to LI-RADS v2018 in consensus (1), and LR-TIV and LR-1 to 5 obser-
vations were excluded, leaving 107 LR-M observations. According to LI-RADS v2018, LR-M is
assigned to either targetoid mass or nontargetoid mass with one of infiltrative appearance,
marked diffusion restriction, necrosis or severe ischemia and other feature that a radiologist
judges to suggest a non-HCC malignancy (1).
Among 107 LR-M observations, one observation was excluded since hepatobiliary phase
signal intensity of the observation could not be compared to the signal intensity of the spleen
due to splenectomy status.
Clinical information and laboratory data of final 106 LR-M observations were then retro-
spectively reviewed and included the following: patient demographics, cause of chronic liver
disease, serum levels of aspartate transaminase, alanine transaminase, total bilirubin, albumin,
prothrombin time, platelets, α-fetoprotein, protein induced by vitamin K absence (PIVKA)-II,
carbohydrate antigen 19–9 (CA 19–9), and carcinoembryonic antigen (CEA).
MR imaging techniques
All patients underwent MRI exam via 3.0-T Magnetom Trio Tim (Siemens Medical Solutions,
Erlangen, Germany), Intera Achieva or Ingenia (Philips Medical Systems, Best, the Nether-
lands), or Discovery MR750w MRI unit (GE Medical Systems, Waukesha, Wis). Dynamic
liver MRI was performed using 10mL of gadoxetate-disodium (Primovist; Bayer AG, Berlin,
Germany) at an injection rate of 1mL/sec, followed by 20mL of 0.9% saline chaser at the same
flow rate (Spectris Solaris MR Injection System; Medrad, Warrendale, PA) [20]. T1 weighted
3D gradient-echo hepatobiliary phase (HBP) was obtained 20 minutes after contrast agent
injection. Other MRI sequences included in routine dynamic liver MRI are written in the
S1 Text.
MR image analysis
One board certified radiologist and a senior radiology resident reviewed MR images using pic-
ture archiving and communication system (PACS) (Centricity Radiology RA 1000; GE Health-
care, Chicago, IL). Both reviewers were blinded to patient’s clinical information and tumor
histopathologic features. Tumor was classified in the dark group when more than 50% of
tumor area showed hypointensity compared to spleen, in the low group when more than 50%
of tumor area showed hyperintensity compared to spleen but hypointensity compared to liver
parenchyma, and in the iso-to-high group if there was even a focal iso-intensity or hyper-
intensity compared to liver parenchyma on visual insepction in hepatobiliary phase image
[21]. When equivocal on visual inspection, region of interest (ROI) was drawn on tumor,
spleen and liver parenchyma to quantify and compare the signal intensities.
Histopathology
Final diagnosis of hepatic observation and status of non-tumor liver parenchyma including
presence of cirrhosis were extracted from pathology reports. For HCC, size, architectural pat-
tern, variant/subtype and major histologic differentiation based on the nuclear grading scheme
proposed by Edmondson and Steiner [22] were recorded. As for non-HCC malignancies, size
and major histologic differentiation (well/moderate/poor/undifferentiated) were recorded.
Presence of tumor necrosis (>5%), percentage of tumor necrosis in gross specimen, capsular
formation status, and microvascular invasion status were recorded for all tumors.
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Statistical analysis
Inter-reader agreement was expressed by Cohen’s kappa coefficient. A kappa statistic of 0.8–
1.0 was considered excellent agreement, 0.6–0.89 good agreement, 0.40–0.59 moderate agree-
ment, 0.2–0.39 fair agreement and 0–0.19 poor agreement. To compare features of HCC and
non-HCC malignancies, we used Mann-Whitney U test for continuous variables and the X2 or
Fisher exact test for categorical variables. The association analyses of hepatobiliary phase signal
intensity group versus tumor group and histopathologic findings were performed by calculat-
ing the Pearson’s correlation coefficients and p values. Bonferroni correction was used for post
hoc multiple comparisons for all statistical analyses. Two-sided p values<0.05 were consid-
ered as statistically significant. All statistical analyses were performed using R software (version
3.4.0; The R Foundation for Statistical Computing, Vienna, Austria).
Results
Diagnostic performance of combined LR-4 and LR-5, LR-5 and LR-M
Based on the eligibility criteria, final LR-categories were assigned to 1286 observations based
on LI-RADS v2018 [1] and are summarized in Fig 1. Overall, the sensitivity and specificity of
LR-4 and LR-5 combined, and LR-5 were 92.9% and 94.9%, and 71.6% and 98.3%, respectively
(S1 Table).
Baseline clinical characteristics of LR-M patients
Baseline patient characteristics are summarized in Tables 1 and 2. Our 106 LR-M patients
comprised of 78 males and 28 females with mean age of 60 ± 11.5 years old. Chronic hepatitis
B was the most predominant cause of underlying liver disease (80% of patients) and 48% had
cirrhosis. Most patients (97%) were of Child Pugh class A and mean size of tumor was 38mm.
The median duration between MRI and surgical pathology was 17 days.
Within 106 LR-M patients, 42 patients (40%) were HCCs and 64 patients (60%) were non-
HCC malignancies. Most HCC patients (34/42, 81%) were of Barcelona Clinic Liver Cancer
(BCLC) stage A and the rest were of BCLC stage 0.
Patients with non-HCC malignancies showed significantly older age (mean age: 62.6 vs.
56.2, P = 0.005), fewer underlying chronic hepatitis B background (73% vs. 91%, P = 0.025),
lower alanine transaminase (ALT) (22.0 vs. 32.0, P = 0.002), α-fetoprotein (3.5 vs. 6.2,
P = 0.019), PIVKA-II (26.0 vs. 47.0, P = 0.003) and higher CA19-9 (37.8 vs. 6.9, P<0.001) com-
pared to patients with HCC (Table 1).
Subgroup analysis of non-HCC malignancies showed that 34% (22/64) had cHCC-CCA
while 61% (39/64) had iCCA (Table 2). The remaining three patients had metastases: one ovar-
ian cancer metastasis and two colon cancer metastases.
Subgroup analysis of LR-M observations showed that the significant differences in age,
albumin, α-fetoprotein, and CA19-9 between HCC with atypical imaging features and non-
HCC malignancies were mainly due to significant differences between HCC and iCCA: age
(P = 0.002), underlying cirrhosis (P = 0.014), albumin (P<0.001), α-fetoprotein (P<0.001) and
CA19-9 (P<0.001) (Table 2).
Hepatobiliary phase signal intensity classification of HCC and non-HCC
malignancies
Out of 106 LR-M observations, 42 observations (40%) were assigned dark, 61 observations
(58%) were assigned low, and 3 observations (3%) were assigned iso-to-high signal intensities
in hepatobiliary phase. Figs 2 and 3 show typical images of LR-M observations with dark, low
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and iso-to-high signal intensity in hepatobiliary phase. Nearly half of 42 dark observations (22,
52%) were found to be HCC while 24% (10/42) and 19% (8/42) were found to be iCCA and
cHCC-CCA, respectively (Table 3). Significant associations between HCC and dark signal
intensity over low signal intensity (P = 0.036) as well as between iCCA or cHCC-CCA or
iCCA and low signal intensity over dark signal intensity (Ps<0.05) were found (Table 3).
These associations were found significant under univariate analyses as well (S2 and S3 Tables).
In case of iso-to-high observations, all three observations were found to be HCC although this
association was not found to be statistically significant (P = 0.060) (S4 Table). Not a single
cHCC-CCA, iCCA or metastasis was found to be iso-to-high in hepatobiliary phase.
Fig 1. Flow diagram of this study.
https://doi.org/10.1371/journal.pone.0257308.g001
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Histopathologic correlation with hepatobiliary phase signal intensity
classification
Histopathologic characteristics of LR-M observations based on hepatobiliary phase signal
intensities are summarized in Table 4. In case of iCCA, cHCC-CCA and metastasis, no signifi-
cant association was found between major histologic differentiation and dark, low and iso-to-
high classification. However, in case of HCC, three observations which showed iso-to-high sig-
nal intensity were Edmondson grade 1 and this association was statistically significant
(P = 0.001) (Fig 3). Moreover, HCCs with iso-to-high signal intensity showed pseudoglandular
architectural pattern (P = 0.012). In addition, while not statistically significant, 7 out of 11 scir-
rhous HCC was found to show low signal intensity (P = 0.078) (Fig 4).
Presence of tumor necrosis (>5%), capsular formation, and microvascular invasion did not
significantly differ among dark, low and iso-to-high groups. However, while the difference was
nonsignificant, dark group showed larger necrotic percentage followed by low and iso-to-high
group (P = 0.090). In case of scirrhous HCCs, those showing dark signal intensity had
Table 1. Baseline characteristics of the included patients.
Variables Total patients (n = 106, 100%) HCC (n = 42, 40%) Non-HCC malignancy (n = 64, 60%) P-value
Age, years 60.0 ± 11.5 56.2 ± 12.0 62.6 ± 10.6 0.005
Sex 0.290
Male 78 (74) 34 (81) 44 (69)
Female 28 (26) 8 (19) 20 (31)
Etiology
Hepatitis B 85 (80) 38 (91) 47 (73) 0.025
Hepatitis C 3 (3) 0 (0) 3 (5) 0.270
Alcohol 12 (11) 2 (5) 10 (16) 0.117
NASH 6 (6) 2 (5) 4 (6) 0.999
Child-Pugh Class 0.999
A 103 (97) 41 (98) 62 (97)
B 3 (3) 1 (2) 2 (3)
Cirrhosis 51 (48) 25 (60) 26 (41) 0.088
AST, IU/L 27 (21–40) 27 (21–44) 27 (21–38) 0.543
ALT, IU/L 25 (18–40) 31 (24–44) 22 (15–38) 0.002
Albumin, g/dL 4.3 (4.1–4.6) 4.5 (4.1–4.6) 4.2 (3.9–4.5) 0.034
Total bilirubin (mg/dL) 0.7 (0.5–1.0) 0.8 (0.6–1.1) 0.7 (0.5–0.9)
PT, INR 0.98 (0.94–1.03) 0.98 (0.94–1.01) 0.98 (0.93–1.05) 0.837
Platelets, 1000/μL 208.4 ± 88.8 184.5 ± 61.0 224.8 ± 100.8 0.012
AFP, IU/mL 5.1 (2.7–51.9) 6.2 (3.5–156.2) 3.5 (2.5–14.9) 0.019
PIVKA-II, AU/mL 31.0 (20.0–121.0) 47.0 (24.0–282.0) 26.0 (18.0–37.0) 0.003
CA 19–9, U/mL 24.8 (8.4–123.0) 6.9 (0.1–13.4) 37.8 (15.3–392.0) <0.001
CEA, ng/mL 2.9 (1.7–4.8) 2.9 (1.6–3.9) 2.9 (1.8–6.0) 0.272
Observation size, mm 38.6 ± 20.4 34.4 ± 16.1 41.4 ± 22.5 0.083
Duration between MRI and surgical pathology, days 17 (10–28) 16 (8–24) 18 (11–33) 0.190
BCLC stage 0 8 (19)
BCLC stage A 34 (81)
Numerical variables are expressed as median (interquartile range) or mean ± standard deviation, according to the result of normality test (Shapiro-Wilk test).
Categorical variables are expressed as n (%). BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma; NASH, non-alcoholic steatohepatitis; AST, aspartate
transaminase; ALT, alanine transaminase; AFP, α-fetorprotein; PIVKA, protein induced by vitamin K absence; CA 19–9, carbohydrate antigen 19–9; CEA,
carcinoembryonic antigen; MRI, magnetic resonance imaging.
https://doi.org/10.1371/journal.pone.0257308.t001
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significantly higher mean tumor necrosis area compared to those showing low signal intensity
(25.0 ± 21.2% vs. 2.5 ± 4.2%, P = 0.027).
Inter-reader agreement of hepatobiliary phase signal intensity classification
Initially, reviewer 1 and reviewer 2 classified 44 (42%) and 43 (41%) as dark group, 59 (56%)
and 60 (57%) as low group, and 3 (3%) and 3 (3%) as iso-to-high group, respectively (Table 5).
The inter-reader agreement for hepatobiliary phase signal intensity classification was excellent,
with a kappa coefficient of 0.872. Excellent inter-reader agreement was observed within HCC
and within non-HCC malignancies with a kappa coefficient of 0.914 and 0.821, respectively.
Discussion
In our study, LR-M observations that showed iso-to-high signal intensity in hepatobiliary
phase were well-differentiated, Edmondson grade 1 HCCs with pseudoglandular architectural
Table 2. Comparison of baseline characteristics of HCC, cHCC-CCA and CCA.
Variables HCC (n = 42, 40%) cHCC-CCA (n = 22, 21%) iCCA (n = 39, 37%) P-value P-valuea P-valueb P-valuec
Age, years 56.2 ± 12.0 59.5 ± 9.6 64.8 ± 10.9 0.005 0.214 0.059 0.002
Sex 0.520
Male 34 (81) 17 (77) 26 (67)
Female 8 (19) 5 (23) 13 (33)
Etiology
Hepatitis B 38 (91) 17 (77) 28 (72) 0.075
Hepatitis C 0 (0) 0 (0) 3 (8) 0.071
Alcohol 2 (5) 3 (14) 6 (15) 0.237
NASH 2 (5) 2 (9) 2 (5) 0.757
Child-Pugh Class 0.874
A 41 (98) 21 (96) 37 (97)
B 1 (2) 1 (5) 1 (3)
Cirrhosis 25 (60) 13 (59) 12 (31) 0.019 0.941 0.057 0.014
AST, IU/L 27 (21–44) 29 (23–58) 27 (20–35) 0.180
ALT, IU/L 31 (24–44) 27 (20–42) 21 (13–34) 0.002 0.325 0.036 <0.001
Albumin, g/dL 4.5 (4.1–4.6) 4.2 (3.9–4.6) 4.3 (4.0–4.4) 0.133
Total bilirubin, mg/dL 0.8 (0.6–1.1) 0.8 (0.7–1.0) 0.7 (0.4–0.9) 0.070
PT, INR 0.98 (0.94–1.01) 1.01 (0.93–1.07) 0.97 (0.92–1.03) 0.683
Platelets, 1000/μL 184.5 ± 61.0 155.0 ± 65.0 223 ± 107.6 <0.001 0.230 <0.001 <0.001
AFP, IU/mL 6.2 (3.5–156.2) 11.6 (2.7–106.4) 2.9 (2.2–4.5) 0.001 0.967 0.002 <0.001
PIVKA-II, AU/mL 47.0 (24.0–282.0) 28.5 (16.0–69.8) 25.0 (18.0–34.0) 0.008 0.048 0.402 0.004
CA 19–9, U/mL 6.9 (0.1–13.4) 10.6 (8.7–36.7) 95.0 (23.7–1478.0) <0.001 0.014 0.016 <0.001
CEA, ng/mL 2.9 (1.6–3.9) 3.2 (1.8–4.9) 2.7 (1.8–5.8) 0.544
Observation size, mm 34.4 ± 16.1 39.1 ± 16.5 36.8 ± 26.0 0.316
Duration between MRI and surgical pathology, days 16 (8–24) 19 (10–24) 21 (12–37) 0.119
Numerical variables are expressed as median (interquartile range) or mean ± standard deviation, according to the result of normality test (Shapiro-Wilk test).
Categorical variables are expressed as n (%). HCC, hepatocellular carcinoma; iCCA, intrahepatic mass-forming cholangiocarcinoma; cHCC-CCA, combined
hepatocellular-cholangiocarcinoma; NASH, non-alcoholic steatohepatitis; AST, aspartate transaminase; ALT, alanine transaminase; AFP, α-fetorprotein; PIVKA,
protein induced by vitamin K absence; CA 19–9, carbohydrate antigen 19–9; CEA, carcinoembryonic antigen; MRI, magnetic resonance imaging.
aPair-wise comparison between HCC and cHCC-CCA.
bPair-wise comparison between cHCC-CCA and iCCA.
cPair-wise comparison between HCC and iCCA.
https://doi.org/10.1371/journal.pone.0257308.t002
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pattern. On the other hand, nearly 70% (43 out of 61) of LR-M observations that showed low
signal intensity in hepatobiliary phase were either cHCC-CCC or iCCA and this association
was significant.
Imaging findings, especially that of hepatobiliary phase signal intensity of tumor may be
useful in differentiating HCC with atypical imaging features from non-HCC malignancies
Fig 2. 46 year old male patient with Edmondson grade III HCC (A-C): rim APHE in (A) late arterial phase and (B) arterial subtraction image, (C) dark signal intensity
in hepatobiliary phase. 74 year old male patient with intrahepatic mass-forming cholangiocarcinoma (D-F): rim APHE in (D) late arterial phase, and (E) arterial
subtraction image, (F) low signal intensity in hepatobiliary phase.
https://doi.org/10.1371/journal.pone.0257308.g002
Fig 3. 73 year old male patient with Edmondson grade I HCC. Rim APHE is shown in (A) late arterial phase, (B) arterial subtraction image and (C) hepatobiliary
phase. This hepatic observations shows iso-to-high signal intensity in hepatobiliary phase.
https://doi.org/10.1371/journal.pone.0257308.g003
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among LR-M observations. Importantly, LR-M observations that showed iso-to-high signal
intensity in hepatobiliary phase were HCCs. LR-M observations showing low signal intensity
in hepatobiliary phase were more significantly associated with cHCC-CCA or iCCA. As for
LR-M observations showing dark signal intensity in hepatobiliary phase, while significant
association was found between dark LR-M and HCC, nearly 40% of dark LR-M also comprised
of either cHCC-CCA or iCCA, making it a difficult differentiator of HCC from non-HCC
malignancies.
In general, tumor signal intensity in hepatobiliary phase is known to decrease significantly
during multistep hepatocarcinogenesis with worse histologic differentiation [23–25]. Consis-
tent with previous studies, the number of iso-to-high signal intensity observations in hepato-
biliary phase was highest in well-differentiated HCCs [23–26]. Expression of organic anion-
transporting polypeptide 8 (OATP8), which is the most probable uptake transporter of
gadoxetic acid, is reported to significantly decrease during multistep hepatocarcinogenesis due
to increased expression of hepatocyte nuclear factor 3β (HNF3β) [25, 27], which may explain
why iso-to-high signal intensity HCCs were confirmed as well-differentiated HCC. Moreover,
iso-to-high signal intensity HCCs were more significantly associated with pseudoglandular
architectural pattern consistent with result of a previous study [24, 28]. Overexpression of
OATP8 is thought to contribute to bile overproduction because OATP8 can also take up bile
acid component, causing pseudoglandular proliferation with bile plugs and secondary dilata-
tion of bile canaliculi [29].
Likewise, significant association between cHCC-CCA or iCCA and low signal intensity in
hepatobiliary is consistent with results of previous studies [30–32]. Such low signal intensity in
hepatobiliary phase is thought to relate to the presence of abundant stromal fibrosis in iCCA
and cholangiocarcinoma component of cHCC-CCA, which causes extracellular accumulation
of contrast agent through large interstitial spaces [31, 33].
Similarly, scirrhous HCC is known to exhibit fibrous tumor stroma generated by cancer-
associated fibroblasts and peritumoral myofibroblasts through cross-talk with HCC cells [34].
In our study, more than half (58%) of scirrhous HCCs showed low signal intensity consistent
with previous studies [35, 36]. Similar to iCCA and cHCC-CCA, scirrhous HCCs that did not
show low signal intensity in hepatobiliary phase showed dark signal intensities. Previously,
Table 3. Hepatobiliary phase (HBP) signal intensities of HCC and non-HCC malignancies.
HBP Signal intensity Dark Low Iso-to-High P-value� P-valuea P-valueb P-valuec
HCC (n = 42, 40%) 22 (52) 17 (41) 3 (7) 0.004 0.036 0.081 0.242
cHCC-CCA (n = 22, 21%) 8 (36) 14 (64) 0 (0) 0.595 0.635 0.999 0.999
iCCA (n = 39, 37%) 10 (26) 29 (74) 0 (0) 0.026 0.045 0.245 0.999
cHCC-CCA or iCCA (n = 61, 58%) 18 (30) 43 (69) 0 (0) 0.001 0.015 0.096 0.264
Metastasis (n = 3, 3%) 2 (67) 1 (33) 0 (0) 0.615 0.565 0.999 0.999
Categorical variables are expressed as n (%). HBP, hepatobiliary phase; HCC, hepatocellular carcinoma; iCCA, intrahepatic mass-forming cholangiocarcinoma;
cHCC-CCA, combined hepatocellular-cholangiocarcinoma.
Dark: signal intensity lower than spleen parenchyma.
Low: signal intensity higher than spleen parenchyma but lower than liver parenchyma.
Iso: signal intensity similar to liver parenchyma.
High: signal intensity higher than liver parenchyma.
�P-value calculated via X2- test or Fisher’s exact test comparing three groups (signal intensity) for each malignancy.
aPairwise comparison between dark group and low group.
bPairwise comparison between low group and iso-to-high group.
cPairwise comparison between dark group and iso-to-high group.
https://doi.org/10.1371/journal.pone.0257308.t003
PLOS ONE Hepatobiliary phase signal intensity of LR-M observations
PLOS ONE | https://doi.org/10.1371/journal.pone.0257308 September 13, 2021 9 / 15
studies on iCCA have reported heterogeneous tumor enhancement pattern in hepatobiliary
phase to be attributed to the amount and density of fibrous component [37], timing of hepato-
biliary phase and predominance of necrosis over fibrosis [38]. Consistent with these findings,
the mean tumor necrosis area was higher in scirrhous HCCs showing dark signal intensities
compared to those showing low signal intensities in our study. Importantly, however, com-
bined together, iCCA, cHCC-CCA and scirrhous HCC comprised 82% of all low signal inten-
sity LR-M observations.
There are some limitations in our study. First, this study may have a selection bias due to its
retrospective design and inclusion of treatment-naiive patients with pathologically confirmed
hepatic observations. However, we only accepted pathologically diagnoses as reference
Table 4. Histopathologic characteristics of malignancies based on HBP signal intensities.
Tumor pathology Data available Dark Low Iso-to-High P-value
HCC (n, %) 22 (52) 17 (40) 3 (7)
Size (mm) 42 35.3 ± 15.9 33.5 ± 18.6 32.2 ± 4.3 0.921
Architectural pattern: 42
Trabecular 22 16 3 0.476
Pseudoglandular 4 4 3 0.012
Compact 1 4 0 0.220
Histologic type 42
Classical 13 9 3 0.880
Macrotrabecular-massive variant 2 0 0 0.566
Scirrhous variant 4 7 0 0.078
Lymphoepithelioma-like variant 3 0 0 0.397
Sarcomatoid variant 0 1 0 0.476
Major histologic differentiation
Grade I / II/ III or IV � 42 0 / 16 / 6 0 / 12 / 5 3 / 0 / 0 0.001
Intrahepatic mass-forming cholangiocarcinoma, iCCA (n, %) 10 (26) 29 (74) 0 (0)
Size (mm) 39 46.5 ± 27.8 42.2 ± 25.4 0.655
Major histologic differentiation
Well / moderate / poor / undifferentiated 38 2 / 6 / 1 / 0 5 / 21 / 3 / 0 0 / 0 / 0 / 0 0.429
Combined hepatocellular cholangiocarcinoma, cHCC-CCA (n, %) 8 (36) 14 (64) 0 (0)
Size (mm) 22 42.2 ± 22.5 37.3 ± 12.5 0.583
Major histologic differentiation
Well / moderate / poor / undifferentiated 22 1 / 5 / 3 1 / 7 / 4 / 1 0 / 0 / 0 / 0 0.892
Metastasis (n, %) 2 (67) 1 (33) 0 (0)
Size (mm) 29.2 ± 16.7 40.0 ± 0 0.691
Major histologic differentiation
Well / moderate / poor / undifferentiated 3 0 / 1 / 1 / 0 0 / 1 / 0 / 0 0 / 0 / 0 / 0 0.667
Total patients (n, %)
Tumor necrosis (>5%)
Absent / Present 105 14 / 28 26 / 34 1 / 2 0.694
Tumor necrosis area, % 105 19.0 ± 23.9 10.9 ± 15.1 6.7 ± 7.6 0.090
Capsular formation
Absent / Partial / Complete 102 22 / 16 / 2 51 / 4 / 4 0 / 2 / 1 0.451
Microvascular invasion
Absent / Present 102 10 / 30 23 / 36 2 / 1 0.144
�Histologic differentiation of HCC is based on Edmondson grade.
https://doi.org/10.1371/journal.pone.0257308.t004
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standards as imaging-histologic correlation is crucial for our analysis and because non-HCC
malignancy such as cHCC-CCA has the potential to be misinterpreted as HCC based on imag-
ing finding alone. Second, as we included pathologically confirmed cases, all of our patients
were of Child Pugh class A or B and all HCC patients were of BCLC stage 0/A for whom diag-
nosis of HCC within LR-M observation would serve a clinical significance as liver transplanta-
tion is one method of curative treatment. However, the enhancement of liver parenchyma in
hepatobiliary phase can be affected by hepatic function [39] and thus whether our method of
classification in hepatobiliary phase is still valid in patients with worse Child-Pugh class and
BCLC stage needs further study. In addition, due to the nature of retrospective study, quality
of hepatobiliary phase image was not judged at the time of image acquisition but instead at the
time of MRI reading. However, if the image quality was not diagnostic, exam was repeated in
daily practice and hence, HBP image was quality-controlled. Third, there has been some
minor modification to imaging protocols during the time period. However, these modifica-
tions were not significant enough to influence interpretation. Fourthly, we used 10mL of
gadoxetate-disodium regardless of patient’s weight as part of our hospital protocol. Lastly,
Fig 4. 46 year old male patient with scirrhous HCC. This observation shows rim APHE in (A) late arterial phase, (B) arterial subtraction image and (C) low signal
intensity in hepatobiliary phase.
https://doi.org/10.1371/journal.pone.0257308.g004
Table 5. Inter-reader agreement of HBP signal intensities.
Reviewer 1 Reviewer 2 K, kappa P-value
Total patients (n = 106) 0.872 <0.001
Dark 44 (42) 43 (41)
Low 59 (56) 60 (57)
Iso-to-High 3(3) 3 (3)
HCC (n = 42, 40%) 0.914 <0.001
Dark 24 (57) 22 (52)
Low 15 (36) 17 (40)
Iso-to-High 3 (7) 3 (7)
Non-HCC malignancies (n = 64, 60%) 0.821 <0.001
Dark 20 (31) 21 (33)
Low 44 (69) 43 (67)
Iso-to-High 0 (0) 0 (0)
A kappa statistic of 0.8–1.0 is considered excellent agreement, 0.6–0.79 good agreement, 0.40–0.59 moderate agreement, 0.2–0.39 fair agreement and 0–0.19 poor
agreement.
https://doi.org/10.1371/journal.pone.0257308.t005
PLOS ONE Hepatobiliary phase signal intensity of LR-M observations
PLOS ONE | https://doi.org/10.1371/journal.pone.0257308 September 13, 2021 11 / 15
image-histologic correlation of fibrous stroma of LR-M observations could not be performed
as this information was not provided in routine pathology report.
In conclusion, LR-M observation showing iso-to-high signal intensity in hepatobiliary
phase may be well-differentiated HCC while LR-M observations showing low signal intensity
in hepatobiliary phase may be tumor with fibrous stroma such as iCCA, cHCC-CCA, or scir-
rhous HCC. Thus, classification of LR-M observations based on hepatobiliary phase signal
intensity may be helpful in differentiating HCC with atypical imaging features from non-HCC
malignancies.
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